Calibr, A Division Of Scripps Research
Clinical trials sponsored by Calibr, A Division Of Scripps Research, explained in plain language.
-
New Parkinson's drug candidate PDM608 begins first human safety tests
Disease control CompletedThis early-phase study tested the safety and tolerability of a new drug called PDM608 in 64 healthy adults. The goal was to see if the drug is safe enough to study further in people with Parkinson's disease. Participants received either PDM608 or a placebo, and researchers monito…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 05, 2026 12:09 UTC